BioCentury | Apr 10, 2020
Product Development

April 9 Quick Takes: BMS tops off CAR T patent win; plus approval for Braftovi plus Erbitux, Merck, BMS, Liquidia, Circassia-AZ, Bridge

...has a PDUFA date of Nov. 24. Phase IIa data for Bridge’s ulcerative colitis therapy Bridge Biotherapeutics Inc....
...Brand), MDX-CTLA-4 (Compound #), MDX-010 (Compound #), BMS-734016 (Compound #), ipilimumab (Generic), Yervoy (Other) Liquidia Technologies Inc. Bridge Biotherapeutics Inc. AstraZeneca...
BioCentury | Mar 11, 2020
Product Development

COVID-19 patients on Ascletis’ HCV drug discharged; plus Mesoblast allogeneic stem cells for COVID-19, Acceleron, Bridge-Atomwise, Cellectis and Abpro

...its AI drug discovery platform to generate compounds against up to 13 targets chosen by Bridge Biotherapeutics Inc....
...Vascular endothelial growth factor BioCentury Staff Ganovo, danoprevir (ASC08, ITMN-191, RG7227, r7227, ITMN B) ACE-083 ABP-100 ABP-201 Ascletis Pharma Inc. Mesoblast Ltd. Bridge Biotherapeutics Inc. Atomwise...
BioCentury | Jan 10, 2020
Company News

Boehringer continues fibrosis drive via acquisition of Enleofen assets

...biotechs, Boehringer added to its IPF pipeline by licensing a Phase I autotaxin inhibitor from Bridge Biotherapeutics Inc....
BioCentury | Dec 19, 2019
Finance

Boehringer deal, clinical milestones support Bridge IPO

...to back Bridge Biotherapeutics' IPO despite several recent setbacks for public Korean biotechs. The strategy of Bridge Biotherapeutics Inc....
...ENPP2 (ATX) - Autotaxin PELI1 (pellino-1) - Pellino E3 ubiquitin protein ligase 1 Stephen Hansen, Associate Editor BBT-877 Bridge Biotherapeutics Inc. IPO Korea...
BioCentury | Sep 27, 2019
Company News

Blade eyeing fibrosis combos with acquisition of PharmAkea-spinout

...is in Phase III to treat idiopathic pulmonary fibrosis (IPF); BBT-887, which Boehringer licensed from Bridge Biotherapeutics Inc....
BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

...one deal, Boehringer expanded its IPF pipeline by licensing a Phase I autotaxin inhibitor from Bridge Biotherapeutics Inc....
...Therapeutics S.A., Geneva, Switzerland Bioharmony Therapeutics Inc., New York, N.Y. Boehringer Ingelheim GmbH, Ingelheim, Germany Bridge Biotherapeutics Inc....
...regulatory protein α SSAO (VAP-1) - Semicarbazide-sensitive amine oxidase Lauren Martz, Associate Editor Bioharmony Therapeutics Inc. Boehringer Ingelheim GmbH Bridge Biotherapeutics Inc. Dicerna...
BioCentury | Jul 18, 2019
Company News

Boehringer deal enables Bridge to expand pipeline, take in-house programs further

...rights to its lung fibrosis candidate BBT-877. The partnership is the second out-licensing deal for Bridge Biotherapeutics Inc....
...E3 ubiquitin protein ligase 1 Associate Editor Lauren Martz contributed to this article. Sandi Wong, Staff Writer Bridge Biotherapeutics Inc. Autotaxin...
BioCentury | Apr 1, 2019
Financial News

Bridge raises $27.2M series C led by UTC, Shinhan

...of Daewoong Pharmaceutical Co. Ltd. (KSE:069620). The financing could be the last private round for Bridge Biotherapeutics Inc....
...ENPP2 (ATX) - Autotaxin; PELI1 (pellino-1) - Pellino E3 ubiquitin protein ligase 1 Mark Zipkin, Staff Writer BBT-401 Bridge Biotherapeutics Inc. Daewoong...
BioCentury | Feb 1, 2019
Company News

Bridge Biotherapeutics gets rights to kinase inhibitor from Korea Research Institute

...Korea Research Institute of Chemical Technology (Daejeon, South Korea) granted Bridge Biotherapeutics Inc. (Seongnam, South Korea) exclusive, worldwide...
...will receive W30 billion ($26.6 million), which includes a signing fee of W1 billion ($886,792). Bridge Biotherapeutics...
...Korea Research Institute of Chemical Technology, Daejeon, South Korea Bridge Biotherapeutics Inc., Seongnam, South Korea Business: Cancer Chris Lieu Bridge Biotherapeutics Inc. Korea...
BioCentury | Dec 21, 2018
Company News

Bridge, Daewoong partner on BBT-401 for ulcerative colitis

...2019. Bridge Biotherapeutics Inc., Seongnam, South Korea Daewoong Pharmaceutical Co. Ltd. (KSE:069620), Seoul, South Korea Business: Autoimmune Sandi Wong BBT-401 Bridge Biotherapeutics Inc. Daewoong...
Items per page:
1 - 10 of 17
BioCentury | Apr 10, 2020
Product Development

April 9 Quick Takes: BMS tops off CAR T patent win; plus approval for Braftovi plus Erbitux, Merck, BMS, Liquidia, Circassia-AZ, Bridge

...has a PDUFA date of Nov. 24. Phase IIa data for Bridge’s ulcerative colitis therapy Bridge Biotherapeutics Inc....
...Brand), MDX-CTLA-4 (Compound #), MDX-010 (Compound #), BMS-734016 (Compound #), ipilimumab (Generic), Yervoy (Other) Liquidia Technologies Inc. Bridge Biotherapeutics Inc. AstraZeneca...
BioCentury | Mar 11, 2020
Product Development

COVID-19 patients on Ascletis’ HCV drug discharged; plus Mesoblast allogeneic stem cells for COVID-19, Acceleron, Bridge-Atomwise, Cellectis and Abpro

...its AI drug discovery platform to generate compounds against up to 13 targets chosen by Bridge Biotherapeutics Inc....
...Vascular endothelial growth factor BioCentury Staff Ganovo, danoprevir (ASC08, ITMN-191, RG7227, r7227, ITMN B) ACE-083 ABP-100 ABP-201 Ascletis Pharma Inc. Mesoblast Ltd. Bridge Biotherapeutics Inc. Atomwise...
BioCentury | Jan 10, 2020
Company News

Boehringer continues fibrosis drive via acquisition of Enleofen assets

...biotechs, Boehringer added to its IPF pipeline by licensing a Phase I autotaxin inhibitor from Bridge Biotherapeutics Inc....
BioCentury | Dec 19, 2019
Finance

Boehringer deal, clinical milestones support Bridge IPO

...to back Bridge Biotherapeutics' IPO despite several recent setbacks for public Korean biotechs. The strategy of Bridge Biotherapeutics Inc....
...ENPP2 (ATX) - Autotaxin PELI1 (pellino-1) - Pellino E3 ubiquitin protein ligase 1 Stephen Hansen, Associate Editor BBT-877 Bridge Biotherapeutics Inc. IPO Korea...
BioCentury | Sep 27, 2019
Company News

Blade eyeing fibrosis combos with acquisition of PharmAkea-spinout

...is in Phase III to treat idiopathic pulmonary fibrosis (IPF); BBT-887, which Boehringer licensed from Bridge Biotherapeutics Inc....
BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

...one deal, Boehringer expanded its IPF pipeline by licensing a Phase I autotaxin inhibitor from Bridge Biotherapeutics Inc....
...Therapeutics S.A., Geneva, Switzerland Bioharmony Therapeutics Inc., New York, N.Y. Boehringer Ingelheim GmbH, Ingelheim, Germany Bridge Biotherapeutics Inc....
...regulatory protein α SSAO (VAP-1) - Semicarbazide-sensitive amine oxidase Lauren Martz, Associate Editor Bioharmony Therapeutics Inc. Boehringer Ingelheim GmbH Bridge Biotherapeutics Inc. Dicerna...
BioCentury | Jul 18, 2019
Company News

Boehringer deal enables Bridge to expand pipeline, take in-house programs further

...rights to its lung fibrosis candidate BBT-877. The partnership is the second out-licensing deal for Bridge Biotherapeutics Inc....
...E3 ubiquitin protein ligase 1 Associate Editor Lauren Martz contributed to this article. Sandi Wong, Staff Writer Bridge Biotherapeutics Inc. Autotaxin...
BioCentury | Apr 1, 2019
Financial News

Bridge raises $27.2M series C led by UTC, Shinhan

...of Daewoong Pharmaceutical Co. Ltd. (KSE:069620). The financing could be the last private round for Bridge Biotherapeutics Inc....
...ENPP2 (ATX) - Autotaxin; PELI1 (pellino-1) - Pellino E3 ubiquitin protein ligase 1 Mark Zipkin, Staff Writer BBT-401 Bridge Biotherapeutics Inc. Daewoong...
BioCentury | Feb 1, 2019
Company News

Bridge Biotherapeutics gets rights to kinase inhibitor from Korea Research Institute

...Korea Research Institute of Chemical Technology (Daejeon, South Korea) granted Bridge Biotherapeutics Inc. (Seongnam, South Korea) exclusive, worldwide...
...will receive W30 billion ($26.6 million), which includes a signing fee of W1 billion ($886,792). Bridge Biotherapeutics...
...Korea Research Institute of Chemical Technology, Daejeon, South Korea Bridge Biotherapeutics Inc., Seongnam, South Korea Business: Cancer Chris Lieu Bridge Biotherapeutics Inc. Korea...
BioCentury | Dec 21, 2018
Company News

Bridge, Daewoong partner on BBT-401 for ulcerative colitis

...2019. Bridge Biotherapeutics Inc., Seongnam, South Korea Daewoong Pharmaceutical Co. Ltd. (KSE:069620), Seoul, South Korea Business: Autoimmune Sandi Wong BBT-401 Bridge Biotherapeutics Inc. Daewoong...
Items per page:
1 - 10 of 17